Ignite Creation Date:
2025-12-24 @ 6:42 PM
Ignite Modification Date:
2026-01-05 @ 11:55 AM
Study NCT ID:
NCT03021057
Status:
UNKNOWN
Last Update Posted:
2019-04-17
First Post:
2017-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
Sponsor:
The University of Hong Kong
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2020-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2020-12
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-11
First Submit QC Date:
None
Study First Post Date:
2017-01-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-15
Last Update Post Date:
2019-04-17
Last Update Post Date Type:
ACTUAL